EP4734982A2 - Mitochondrialer komplex i inhibitoren mit reduzierter phosphodiesterase hemmung - Google Patents

Mitochondrialer komplex i inhibitoren mit reduzierter phosphodiesterase hemmung

Info

Publication number
EP4734982A2
EP4734982A2 EP24833137.3A EP24833137A EP4734982A2 EP 4734982 A2 EP4734982 A2 EP 4734982A2 EP 24833137 A EP24833137 A EP 24833137A EP 4734982 A2 EP4734982 A2 EP 4734982A2
Authority
EP
European Patent Office
Prior art keywords
equiv
alkyl
mmol
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24833137.3A
Other languages
English (en)
French (fr)
Inventor
Nicholas Denko
Mark MITTON-FRY
Ben HAINES
Martin BENEJ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of EP4734982A2 publication Critical patent/EP4734982A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP24833137.3A 2023-06-29 2024-07-01 Mitochondrialer komplex i inhibitoren mit reduzierter phosphodiesterase hemmung Pending EP4734982A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363524052P 2023-06-29 2023-06-29
PCT/US2024/036369 WO2025007113A2 (en) 2023-06-29 2024-07-01 Mitochondrial complex i inhibitors with reduced phosphodiesterase inhibition

Publications (1)

Publication Number Publication Date
EP4734982A2 true EP4734982A2 (de) 2026-05-06

Family

ID=93939971

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24833137.3A Pending EP4734982A2 (de) 2023-06-29 2024-07-01 Mitochondrialer komplex i inhibitoren mit reduzierter phosphodiesterase hemmung

Country Status (2)

Country Link
EP (1) EP4734982A2 (de)
WO (1) WO2025007113A2 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
HUP0102793A3 (en) * 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
MX2007004403A (es) * 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
US7977346B2 (en) * 2006-01-17 2011-07-12 Guoqing Paul Chen Spiro compounds and methods of use
KR102327054B1 (ko) * 2017-08-29 2021-11-17 기초과학연구원 퀴놀린 유도체 및 alk와 변이된 alk의 저해제로서의 용도

Also Published As

Publication number Publication date
WO2025007113A3 (en) 2025-06-12
WO2025007113A2 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
WO2022228387A1 (en) Compounds as parp inhibitors
WO2024153070A1 (en) Glp-1r agonists and uses thereof
AU2013240340B2 (en) PFKFB3 inhibitor and methods of use as an anti-cancer therapeutic
JP6559719B2 (ja) （ｓ）−６−（（１−アセチルピペリジン−４−イル）アミノ）−ｎ−（３−（３、４−ジヒドロイソキノリン−２（１ｈ）−イル）−２−ヒドロキシプロピル）ピリミジン−４−カルボキサミドの結晶塩
CN102286050A (zh) 用于肿瘤靶向治疗的含葡萄糖铂配合物及其制备方法
CN102824346B (zh) 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤
CN102276674A (zh) 用于肿瘤靶向治疗的含半乳糖铂配合物及其制备方法
CN103483158A (zh) 一种二苯乙烷衍生物及其应用
WO2023039573A1 (en) Compounds for targeted degradation of taf1
EP2139463B1 (de) Antiinfektiöse mittel
CN111377873A (zh) 氨基嘧啶化合物及其制备方法和用途
AU2023306375A1 (en) Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
WO2022155593A1 (en) Inhibitors and degraders of janus kinase 2
WO2025007113A2 (en) Mitochondrial complex i inhibitors with reduced phosphodiesterase inhibition
JP2015535239A (ja) 抗腫瘍性および抗増殖性の薬剤としての１−（置換スルホニル）−２−アミノイミダゾリンの誘導体
JPH03500533A (ja) 医薬品に安定な白金化合物
ITMI971594A1 (it) Platino complessi cationici tetra- e penta-nucleari ad attivita' antitumorale
CN102875606B (zh) 一种双膦酸铜配合物、其制备方法及用途
WO2024035771A2 (en) Ulk3 inhibitors and uses thereof
WO2022226290A1 (en) 2-phenylamino pyrrolopyrimidines as ack1 inhibitors
WO2025226846A1 (en) Cdk12 inhibitors with imidazole[1,2-a] pyrazines
AU2022394660A1 (en) Compounds as bcl-2 inhibitors
CN103214467A (zh) 5-[[4-[(2，3-二甲基-2h-吲唑-6-基)甲氨基]-2嘧啶基]氨基]-2-甲基-苯磺酰胺衍生物及其制备方法与应用
WO2024124092A2 (en) Prodrugs of temozolomide to facilitate delivery into brain tumors
WO2024226423A1 (en) Helicase inhibitors

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260126

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR